Imatinib Lek-Am (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream phosphorylation events, halting uncontrolled cell division and inducing apoptosis in malignant cells that rely on these signaling pathways.

The exact dose of Imatinib Lek-Am is determined by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

The safety of Imatinib during pregnancy and lactation is not well established. It is classified as having an unknown pregnancy category, and potential risks to the fetus or infant cannot be ruled out. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer faster molecular responses in some patients, but Imatinib’s long‑term safety profile and extensive clinical experience make it a widely used reference therapy.

Imatinib Lek-Am should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet potency throughout its shelf life.

Imatinib Lek-Am is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow any specific instructions regarding timing relative to meals.

Serious risks include severe neutropenia or leukopenia, hepatotoxicity, and cardiac failure or reduced left‑ventricular function. Patients should be monitored regularly for blood‑cell counts, liver enzymes and cardiac status, and any signs of these complications should prompt immediate medical evaluation.

Imatinib is contraindicated in individuals with known hypersensitivity to Imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe hepatic impairment, uncontrolled heart failure, or those taking medications that strongly interact with its metabolism.